People who have been treated with rituximab, a widely used cancer drug, or similar drugs respond poorly or not at all to subsequent COVID-19 mRNA vaccines, according to a study by researchers at Stanford Medicine.
People who have been treated with rituximab, a widely used cancer drug, or similar drugs respond poorly or not at all to subsequent COVID-19 mRNA vaccines, according to a study by researchers at Stanford Medicine.